<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00285467</url>
  </required_header>
  <id_info>
    <org_study_id>0508-06</org_study_id>
    <nct_id>NCT00285467</nct_id>
  </id_info>
  <brief_title>Cholecalciferol Versus Doxercalciferol in the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease</brief_title>
  <official_title>Comparison of Cholecalciferol Versus Doxercalciferol in the Treatment of Secondary Hyperparathyroidism in CKD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The majority of patients with moderate to severe chronic kidney disease (CKD) (stages 3 and
      4) develop secondary hyperparathyroidism (2°HPT), but the optimal therapy to control
      hyperparathyroidism in this group is unknown. The National Kidney Foundation presented
      guidelines in 2003 recommending vitamin D supplementation for vitamin D insufficient patients
      and active vitamin D therapy in patients with sufficient levels. These guidelines are based
      on opinion since there are no significant trials to determine if vitamin D supplementation is
      effective in this population. The active vitamin D metabolites doxercalciferol, paricalcitol,
      and calcitriol have been shown to effectively suppress parathyroid hormone (PTH), but have
      not been compared with vitamin D supplementation with a calciferol (ergocalciferol or
      cholecalciferol). Beyond hyperparathyroidism, small studies suggest vitamin D replacement in
      vitamin D insufficient non-CKD subjects result in improved pain, feeling of well being, blood
      pressure and strength. In this proposed study we wish to directly compare the effectiveness
      of cholecalciferol versus doxercalciferol in suppressing elevated PTH levels in subjects with
      CKD not on dialysis who have vitamin D insufficiency in a three month study. Secondary
      endpoints will be change in blood pressure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with CKD stage 3 were randomly allocated (by blinded group allocation) to either
      cholecalciferol (4000 U per day for one month then 2000 IU daily thereafter) or
      doxercalciferol (2.5 mcg po daily. Assessments for blood endpoints (primary end point PTH;
      secondary calcium, phosphorus) were done monthly. Other assessments (blood pressure) were
      done at baseline and at 3 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Reduction in PTH</measure>
    <time_frame>3 month</time_frame>
    <description>Percent reduction in PTH from baseline to 3 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Systolic Blood Pressure at 3 Months</measure>
    <time_frame>3 month</time_frame>
    <description>systolic blood pressure at 3 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Renal Osteodystrophy</condition>
  <arm_group>
    <arm_group_label>Doxercalciferol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>doxercalciferol 1 mcg capsule orally daily for 3 months. This is a form of vitamin D that does not require activation by enzymes in the liver and kidney.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cholecalciferol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>cholecalciferol 4000 IU capsule orally daily for one month, then 2000 IU capsule daily orally for 2 months. this form of vitamin D requires activation by cells of the body.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxercalciferol</intervention_name>
    <description>form of vitamin D that is already in active form.</description>
    <arm_group_label>Doxercalciferol</arm_group_label>
    <other_name>Hectoral</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cholecalciferol</intervention_name>
    <description>from of vitamin D that requires cells in the body to make active</description>
    <arm_group_label>Cholecalciferol</arm_group_label>
    <other_name>vitamin D3</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 18 years old or older, male or female

          -  able to sign informed consent

          -  CKD stage 3 (GFR 30-59 ml/min) or stage 4 (15-29 ml/min)

          -  intact Parathyroid hormone level (iPTH) &gt; 100 pg/ml for stage 3 or iPTH &gt; 150 pg/ml
             for stage 4

          -  calcidiol levels ≤ 20 ng/ml

          -  ability to ambulate without assistance

        Exclusion Criteria:

          -  intact PTH &gt; 400 pg/ml

          -  initial corrected Calcium &gt; 9.7 mg/dl

          -  initial serum Phosphorous &gt; 5.0 mg/dl

          -  initial standardized blood pressure of &gt; 160/100

          -  history of significant liver disease or cirrhosis

          -  anticipated requirement for dialysis in 6 months

          -  malabsorption, severe chronic diarrhea, or ileostomy

          -  no calcimimetic or active vitamin D therapy 30 days prior to enrollment

          -  use of digoxin, magnesium containing products, mineral oil, or cholestyramine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>82 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sharon Moe, MD</last_name>
    <role>Study Director</role>
    <affiliation>Indiana University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indiana University School of Medicine</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Moe SM, Saifullah A, LaClair RE, Usman SA, Yu Z. A randomized trial of cholecalciferol versus doxercalciferol for lowering parathyroid hormone in chronic kidney disease. Clin J Am Soc Nephrol. 2010 Feb;5(2):299-306. doi: 10.2215/CJN.07131009. Epub 2010 Jan 7.</citation>
    <PMID>20056760</PMID>
  </results_reference>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2006</study_first_submitted>
  <study_first_submitted_qc>January 31, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2006</study_first_posted>
  <results_first_submitted>March 27, 2012</results_first_submitted>
  <results_first_submitted_qc>April 18, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 2, 2016</results_first_posted>
  <last_update_submitted>April 18, 2016</last_update_submitted>
  <last_update_submitted_qc>April 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>kidney, parathyroid hormone, vitamin d</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperparathyroidism</mesh_term>
    <mesh_term>Hyperparathyroidism, Secondary</mesh_term>
    <mesh_term>Chronic Kidney Disease-Mineral and Bone Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>1 alpha-hydroxyergocalciferol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Doxercalciferol, Active Vitamin D</title>
          <description>Doxercalciferol is an active Vitamin D readily usable by human body.</description>
        </group>
        <group group_id="P2">
          <title>Cholecalciferol, Inactive Vitamin D</title>
          <description>Cholecalciferol is inactive Vitamin D and requires the kidneys to make it active.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>47 subjects had at least one follow up visit after taking medications and were included in results.</population>
      <group_list>
        <group group_id="B1">
          <title>Doxercalciferol, Active Vitamin D</title>
          <description>Doxercalciferol is an active Vitamin D readily usable by human body.</description>
        </group>
        <group group_id="B2">
          <title>Cholecalciferol, Inactive Vitamin D</title>
          <description>Cholecalciferol is inactive Vitamin D and requires the kidneys to make it active.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="22"/>
            <count group_id="B3" value="47"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65" spread="10"/>
                    <measurement group_id="B2" value="62" spread="10"/>
                    <measurement group_id="B3" value="63.5" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>55 subjects were consents and underwent qualifying blood tests. 47 subjects were randomized to treatment: 25 to doxercalciferol and 22 to cholecalciferol.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Reduction in PTH</title>
        <description>Percent reduction in PTH from baseline to 3 months</description>
        <time_frame>3 month</time_frame>
        <population>The initial sample size was based on the published response to doxercalciferol versus placebo where a 46% reduction in PTH was observed over 6 months, with a 51% SD. The expected reduction in PTH with cholecalciferol was based on the best-case scenario decrease of 17.8% in PTH with ergocalciferol from our own clinic setting.</population>
        <group_list>
          <group group_id="O1">
            <title>Doxercalciferol, Active Vitamin D</title>
            <description>Doxercalciferol is an active Vitamin D readily usable by human body.</description>
          </group>
          <group group_id="O2">
            <title>Cholecalciferol, Inactive Vitamin D</title>
            <description>Cholecalciferol is inactive Vitamin D and requires the kidneys to make it active.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Reduction in PTH</title>
          <description>Percent reduction in PTH from baseline to 3 months</description>
          <population>The initial sample size was based on the published response to doxercalciferol versus placebo where a 46% reduction in PTH was observed over 6 months, with a 51% SD. The expected reduction in PTH with cholecalciferol was based on the best-case scenario decrease of 17.8% in PTH with ergocalciferol from our own clinic setting.</population>
          <units>% change in PTH baseline to 3 months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27" spread="34"/>
                    <measurement group_id="O2" value="10" spread="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systolic Blood Pressure at 3 Months</title>
        <description>systolic blood pressure at 3 months</description>
        <time_frame>3 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Doxercalciferol, Active Vitamin D</title>
            <description>Doxercalciferol is an active Vitamin D readily usable by human body.</description>
          </group>
          <group group_id="O2">
            <title>Cholecalciferol, Inactive Vitamin D</title>
            <description>Cholecalciferol is inactive Vitamin D and requires the kidneys to make it active.</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Blood Pressure at 3 Months</title>
          <description>systolic blood pressure at 3 months</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120" spread="47"/>
                    <measurement group_id="O2" value="128" spread="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Doxercalciferol, Active Vitamin D</title>
          <description>Doxercalciferol is an active Vitamin D readily usable by human body.</description>
        </group>
        <group group_id="E2">
          <title>Cholecalciferol, Inactive Vitamin D</title>
          <description>Cholecalciferol is inactive Vitamin D and requires the kidneys to make it active.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Larger, long term studies are needed to demonstrate efficacy of mineral-related and non-mineral-related endpoints and safety.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Sharon Moe, MD</name_or_title>
      <organization>Indiana University School of Medicine</organization>
      <phone>317-278-2868</phone>
      <email>smoe@iupui.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

